Condition: Non-muscle Invasive Bladder Cancer (NMIBC) · Sponsor: Suzhou Forlong Biotechnology Co., Ltd
The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG. To evaluate the preliminary efficacy of FL115 alone or in combination with BCG in the treatment of NMIBC. The study consists of three parts: FL115 monotherapy dose escalation (Phase Ia), FL115 combined with BCG dose escalation (Phase Ib), and FL115 combined with BCG cohort expansion (Phase II). Each subject will receive FL115 alone or in combination with intravesical BCG, administered over three treatment periods: induction, enhanced induction/maintenance 1, and maintenance 2.
This description comes directly from the study's public registry record.
Xuxiajun Medical Director · +86-18101882657 · xiajunxu@forlongbiotech.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Fujian, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Recruiting |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Recruiting |
| Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital | Chengdu, Sichuan, China | Recruiting |
| The Second Hospital of Tianjin Medical University | Tianjin, Tianjin Municipality, China | Recruiting |
| Fudan University Cancer Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07122414